Samsara BioCapital LLC Has $28.49 Million Stock Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Samsara BioCapital LLC cut its holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 18.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 986,981 shares of the company's stock after selling 221,492 shares during the quarter. LENZ Therapeutics comprises approximately 3.9% of Samsara BioCapital LLC's portfolio, making the stock its 7th largest holding. Samsara BioCapital LLC owned about 3.59% of LENZ Therapeutics worth $28,494,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in LENZ. Jane Street Group LLC acquired a new stake in shares of LENZ Therapeutics in the 3rd quarter worth $286,000. Barclays PLC lifted its position in shares of LENZ Therapeutics by 273.1% during the 3rd quarter. Barclays PLC now owns 16,463 shares of the company's stock valued at $391,000 after acquiring an additional 12,051 shares during the period. Harbor Capital Advisors Inc. acquired a new stake in shares of LENZ Therapeutics in the 4th quarter worth approximately $1,270,000. SG Americas Securities LLC raised its holdings in LENZ Therapeutics by 20.7% during the fourth quarter. SG Americas Securities LLC now owns 5,458 shares of the company's stock worth $158,000 after purchasing an additional 935 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in LENZ Therapeutics during the fourth quarter worth $168,000. Hedge funds and other institutional investors own 54.32% of the company's stock.

LENZ Therapeutics Stock Performance

Shares of NASDAQ:LENZ traded up $0.64 during trading on Friday, reaching $29.52. 267,059 shares of the stock were exchanged, compared to its average volume of 185,099. The firm's 50-day moving average price is $24.07 and its 200 day moving average price is $27.28. The firm has a market cap of $813.07 million, a price-to-earnings ratio of -6.19 and a beta of 0.43. LENZ Therapeutics, Inc. has a 12-month low of $14.42 and a 12-month high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04). As a group, equities research analysts forecast that LENZ Therapeutics, Inc. will post -2.18 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on LENZ. Piper Sandler initiated coverage on shares of LENZ Therapeutics in a research note on Monday, April 14th. They issued an "overweight" rating and a $51.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $38.00 price target on shares of LENZ Therapeutics in a report on Wednesday, April 16th. Citigroup boosted their price target on LENZ Therapeutics from $44.00 to $47.00 and gave the company a "buy" rating in a report on Thursday, March 20th. Finally, TD Cowen began coverage on LENZ Therapeutics in a research report on Tuesday, March 18th. They issued a "buy" rating and a $60.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $46.60.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.